Keywords: abbott, says, atrasentan, trial, misses, endpoint, laboratories

Abbott says atrasentan trial misses endpoint

Article | 17 February 2003

Print This

Abbott Laboratories has halted a Phase III trial of one its late-stagepipeline drugs, atrasentan for prostate cancer, after the study ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in